TD Cowen analyst Stacy Ku initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and no price target The company’s AVTX-009 is in a Phase II trial for hidradenitis suppurativa, with data expected in mid-2026, the analyst tells investors in a research note. The firm says key opinion leaders highlight the heterogeneous patient population and high unmet need. The leaders expect success with AVTX-009 with potential for a $1B-plus sales opportunity.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Target downgraded, Salesforce upgraded: Wall Street’s top analyst calls
- Avalo Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Avalo Therapeutics Reports Q2 2025 Financial Results
- Avalo Therapeutics: Promising Phase 2 Trial and Market Opportunities Drive Buy Rating
- Avalo Therapeutics reports Q2 EPS ($1.92), consensus ($1.48)